RT Journal Article
SR Electronic
T1 Machine Learning with Objective Serum Markers and Algorithmic Deep Learning Computed Tomography Scan Analysis for Classification of Brain Injury
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.13.21250776
DO 10.1101/2021.02.13.21250776
A1 Rafter, Daniel
A1 Li, Zhuliu
A1 Schaaf, Tory
A1 Gault, Kristen
A1 Thorpe, Maxwell
A1 Venkatesh, Shivani
A1 Edpuganti, Radhika
A1 Song, Tianci
A1 Kuang, Rui
A1 Samadani, Uzma
YR 2021
UL http://medrxiv.org/content/early/2021/06/16/2021.02.13.21250776.abstract
AB Background Brain injury is pathophysiologically diverse, with many cases presenting with mixed pathologies. Utilizing objective measures to investigate the pathophysiology of injury would aid in understanding prognosis and targeting therapeutics.Objective The goal of this study is to develop a traumatic brain injury classification scheme based on open source deep learning computer tomography (CT) analysis and the two serum biomarkers, glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal L1 (UCH-L1).Methods Machine learning was utilized to develop a novel algorithm capable of classifying the type of brain injury based on a CT scan analysis algorithm and GFAP and UCH-L1 concentrations. Injury was stratified into one of four groups: spontaneous hemorrhage, oxygen deprivation, trauma resulting in vascular injury or high-velocity trauma with negative CT scan.Outcomes 100 research subjects were enrolled. Using a combination of CT analysis and serum markers, the subjects with CT positive trauma were distinguishable from those with spontaneous hemorrhage, ischemic injury, CT negative trauma and controls with AUCs of 0.96, 0.99., 0.98 and 1.00 respectively. Ischemic injury was distinguishable from CT positive trauma with an AUC of 0.98. All forms of brain injury could be distinguished from controls with AUC = 1.00.Discussion An open source algorithmic CT scan analysis algorithm and serum biomarkers accurately classified the nature of brain injury across major etiologies. Further implementation of such algorithms and addition of other objective measures will enable better prognostication of injury and improved development of therapeutics.Competing Interest StatementDr. Samadani reports grants from Abbott Diagnostic Laboratories, grants from Minnesota State Office of Higher Education, during the conduct of the study; personal fees from Abbott Diagnostic Laboratories, personal fees from The American Association of Neuroscience Nurses, personal fees from Cottage Health, personal fees from Google Inc., personal fees from Integra Corp, personal fees from Medtronic Corp, personal fees from National Neurotrauma Society, personal fees from Minnesota, Texas, Louisiana and Wisconsin Coaches Associations, personal fees from National Football League and USA Football, other from National Football League, other from Oculogica Inc., other from Veterans Administration, outside the submitted work .Clinical TrialNCT02706574Funding StatementThis study was funded by Abbott Labs and the Minnesota State Office of Higher Education Project Number 176016. Neither played a role in generation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hennepin Healthcare Institutional Review Board approval (HSR #15-4079) was obtained for prospective enrollment of patients who presented to the emergency department of a level-1 trauma center between May 2016 and April 2017All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request. https://tracktbi.ucsf.edu/transforming-research-and-clinical-knowledge-tbi